- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09:30 | UK Stock Market News: Aptamer, MicroSalt, HICL | 1 | The Armchair Trader | ||
| 08:00 | Aptamer Group PLC - Contract extension with global pharma partner | 2 | RNS | ||
| 08.08. | Aptamer Group PLC - Investor Technical Webinar | 1 | RNS | ||
| 04.08. | AIM Market Roundup: Westmount Energy, Aptamer, Europa Oil & Gas | 1 | The Armchair Trader | ||
| APTAMER GROUP Aktie jetzt für 0€ handeln | |||||
| 31.07. | Aptamer Group PLC - Investor Webinar | - | RNS | ||
| 31.07. | Aptamer Group PLC - Trading Update | 1 | RNS | ||
| 24.07. | Aptamer Group PLC - Result of General Meeting | 1 | RNS | ||
| 21.07. | TRADING UPDATES: Aptamer gets more Unilever work; Creo 'confident' | 16 | Alliance News | ||
| 21.07. | Aptamer gets more commissioned work from Unilever | 9 | Sharecast | ||
| 21.07. | Aptamer Group PLC - Additional work commissioned by Unilever | 16 | RNS | ||
| 18.07. | Aptamer Group PLC - Issue of Equity in lieu of Non-Exec Director Fees | - | RNS | ||
| 08.07. | Aptamer Group PLC - Posting of Circular and Notice of General Meeting | 1 | RNS | ||
| 04.07. | IN BRIEF: Aptamer raises £2 million for Optimer commercialisation | - | Alliance News | ||
| 04.07. | Aptamer raises £2m to support expanding its Optimer technology | 2 | Sharecast | ||
| 04.07. | Aptamer Group PLC - Placing to raise £2.0 million | 1 | RNS | ||
| 30.06. | Aptamer Group PLC - Liver fibrosis breakthrough with Optimer® platform | - | RNS | ||
| 25.06. | Aptamer Group PLC - Agreement with global life sciences leader | - | RNS | ||
| 30.05. | Aptamer signs second Optimer programme contract with Unilever | 5 | Sharecast | ||
| 30.05. | Aptamer cheers second product development deal with Unilever | 3 | Alliance News | ||
| 30.05. | Aptamer Group PLC - Unilever second Optimer development programme | 5 | RNS |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DYNE THERAPEUTICS | 12,380 | -1,12 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,550 | +1,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| BOLT PROJECTS | 8,910 | +4,82 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,105 | -0,05 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,765 | +2,22 % | Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid | ||
| ARS PHARMACEUTICALS | 14,540 | +0,48 % | ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales | ||
| IMMUNOME | 10,280 | +3,32 % | Immunome Inc. - 10-Q, Quarterly Report | ||
| LENZ THERAPEUTICS | 37,870 | -7,43 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,690 | +0,91 % | Summit Therapeutics: Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 | Ivonescimab to be Featured at WCLC Presidential Symposium for Second Consecutive Year
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the... ► Artikel lesen | |
| VALNEVA | 5,285 | +10,89 % | Valneva: Operativer Cashburn deutlich verringert - Umsatz steigt | Valneva hat im ersten Halbjahr 2025 die Gesamterlöse um 37,8 Prozent auf 97,6 Millionen Euro gesteigert. Der Umsatz aus Produktverkäufen stieg um 33,3 Prozent auf 91 Millionen Euro. Das Unternehmen... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 4,520 | +1,80 % | Vir Biotechnology, Inc.: Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart elebsiran without or with PEG-IFNa, respectively As previously... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 6,820 | +3,33 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen | |
| ARCELLX | 74,01 | +2,99 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,990 | +0,12 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 3,335 | -2,77 % | Sana Biotechnology drops Washington plant build-out, pivots to CDMOs instead |
Das Unternehmen APTAMER GROUP PLC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,001 (+10,00 %) liegt der Kurs bei 0,006 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APTAMER GROUP PLC finden Sie auf Wallstreet Online.